Comparative Pharmacology
Head-to-head clinical analysis: DODEX versus HYDROXOMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DODEX versus HYDROXOMIN.
DODEX vs HYDROXOMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a synthetic form of vitamin B12, which acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also acts as a direct scavenger of cyanide ions by binding to them to form cyanocobalamin, which is excreted renally.
1 mg intramuscularly once every 7-10 days for maintenance; 1 mg intramuscularly once daily for 7 days for initial treatment.
100 mg intramuscularly or deep subcutaneously three times a week.
None Documented
None Documented
Terminal elimination half-life is approximately 6 days (range 4-10 days) in plasma; however, due to extensive tissue binding and enterohepatic recirculation, the pharmacodynamic half-life for correction of deficiency is about 1 year.
Terminal elimination half-life approximately 4-6 hours; may extend to 8-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Primarily renal: ~50-80% of absorbed dose excreted unchanged in urine via glomerular filtration. Biliary/fecal excretion accounts for <10% as cyanocobalamin.
Primarily renal (80-90% unchanged) with minor biliary/fecal elimination (5-10%); total clearance ~150 mL/min.
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement